With access to higher throughput benchtop bioreactors, our customers are able to screen strains and optimize processes in parallel.
One of the primary motivations for building our own bioreactors was having the ability to quickly scale our capacity. We want to offer biotech companies the ability to do high-throughput fermentation experiments quickly and easily so that they can get the data they need to get to market sooner. Instead of phasing out experiments based on bioreactor capacity constraints, our goal is to enable clients to run massive parallel experiments to strain screens or optimize processes in one shot. Last month, one of our clients set a new record for us by running 52 bioreactor experiments in parallel. Taking advantage of our high-throughput capabilities, they did strain screening and process development work simultaneously. They were looking to see which process/strain combination gave the highest product titer. Check out some of the data outputs from these experiments below.